Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review (Q34836818)

4 August 2017

1 reference

title

Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review (English)

1 reference

postmenopausal osteoporosis

4 August 2017

0 references

1 reference

Raheem B Kherani

1

1 reference

4 August 2017

Alexandra Papaioannou

series ordinal

2

1 reference

4 August 2017

Jonathan D Adachi

series ordinal

3

1 reference

4 August 2017

1 January 2002

1 reference

4 August 2017

1 reference

4 August 2017

25

1 reference

4 August 2017

11

1 reference

4 August 2017

781-790

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200225110-00003

4 August 2017

0 references

cites work

Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women

1 reference

12 December 2020

Alendronate and naproxen are synergistic for development of gastric ulcers

1 reference

12 December 2020

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

12 December 2020

Gastric and duodenal safety of daily alendronate

1 reference

12 December 2020

Esophagitis associated with the use of alendronate

1 reference

12 December 2020

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

12 December 2020

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

1 reference

12 December 2020

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

12 December 2020

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

1 reference

12 December 2020

An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae

1 reference

12 December 2020

The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study

1 reference

12 December 2020

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

12 December 2020

Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage

1 reference

12 December 2020

Tolerability of risedronate in postmenopausal women intolerant of alendronate

1 reference

12 December 2020

Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy

1 reference

12 December 2020

A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group

1 reference

12 December 2020

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

1 reference

12 December 2020

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

1 reference

12 December 2020

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

12 December 2020

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Economic implications of hip fracture: health service use, institutional care and cost in Canada.

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers

1 reference

12 December 2020

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

12 December 2020

Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis

1 reference

12 December 2020

Management of corticosteroid-induced osteoporosis

1 reference

12 December 2020

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

1 reference

12 December 2020

Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms

1 reference

12 December 2020

Severe oral ulcerations induced by alendronate

1 reference

12 December 2020

10.2165/00002018-200225110-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference